← Back to Search

IMM2510 in Advanced Solid Tumors for Solid Tumors

Phase 1
Recruiting
Research Sponsored by ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during 28 days after the first dose of imm2510, all patients included
Awards & highlights

Summary

This trial is a first-in-human, open-label, multi-center, dose escalation phase 1a study followed by cohort expansion phase 1b study to evaluate the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of IMM2510, a PD-L1 and VEGF bispecific fusion protein, in patients with advanced solid tumors.

Eligible Conditions
  • Solid Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during 28 days after the first dose of imm2510, all patients included
This trial's timeline: 3 weeks for screening, Varies for treatment, and during 28 days after the first dose of imm2510, all patients included for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
AEs
Changes in Electrocardiogram
Changes in Laboratory Test Result
+4 more
Secondary study objectives
AUC0-inf
AUC0-tau
AUC0-tlast
+15 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: IMM2510 in Advanced Solid TumorsExperimental Treatment1 Intervention
IMM2510 Phase 1a Dose Escalation: 0.007 mg/kg, 0.03 mg/kg, 0.1 mg/kg, 1.0 mg/kg, 3.0 mg/kg, 6.0 mg/kg, 10 mg/kg, 20 mg/kg, or higher dose, through intravenous administration every 2 weeks up to 52 weeks. Phase 1b Cohort Expansion: multiple cohorts are planned, including, but not limited to: non-small cell lung cancer, liver cancer, cervical cancer, cholangiocarcinoma, pancreatic cancer and renal cell carcinoma, with at least 12 patients enrolled in each cohort to further explore the safety and efficacy of IMM2510 in different tumors. The dose for expansion is given by intravenous infusion up to 52 weeks.

Find a Location

Who is running the clinical trial?

Zhejiang Cancer HospitalOTHER
331 Previous Clinical Trials
784,267 Total Patients Enrolled
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.Lead Sponsor
13 Previous Clinical Trials
1,424 Total Patients Enrolled
Fudan UniversityOTHER
1,185 Previous Clinical Trials
1,629,627 Total Patients Enrolled
~26 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top